Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Angle Plc LSE:AGL London Ordinary Share GB0034330679 ORD 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.50 -0.94% 52.50 51.00 54.00 53.00 52.00 53.00 225,728 12:50:36
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 1.0 -17.4 -6.7 - 137

Angle Share Discussion Threads

Showing 22951 to 22974 of 24975 messages
Chat Pages: Latest  927  926  925  924  923  922  921  920  919  918  917  916  Older
DateSubjectAuthorDiscuss
03/10/2022
16:23
Gspanner. I was going to post that. I expect another TR1 pretty soon.
purchaseatthetop
03/10/2022
16:22
Why on earth would I want to go to any event that you are at amaretto? This is internet, not real life. And yes, I will be logging on at My ambulance station at 7.30am tomorrow morning. So will continue doing that. Mind the traffic.
purchaseatthetop
03/10/2022
16:17
We posted it on the AHT thread at 10 pence ...Maybe you really should stick to Ambulance driveing
amaretto1
03/10/2022
16:16
Don't worry ... you are not invited !!
amaretto1
03/10/2022
16:14
That is a really bad idea. People post that kind of idea on pump and dump threads like EUA, SYME, BEN etc.

Loads of volume in the last hour though. Looks set for a good Tuesday.

purchaseatthetop
03/10/2022
16:13
When we hit 500 pence share price We should all meet up in london !Did the same once with AHT gang..AHT went from 3 pence to 60 pounds With NO dilutions....Yes you read that right !!!
amaretto1
03/10/2022
16:09
Bagpuss, one of the good things about the Shares presentation was that there was a Q&A session at the end of the presentation. To AN’s & IG’s great credit they gave direct answers to all the the questions. One of the questions (thanks SK) was about the Abbott collaboration and the answer was very positive.

Question -
“Angle collaborated with Abbott in the metastatic breast cancer trial that led to the FDA approval. Now that you've got approval, how do you see your relationship with Abbott developing?”

AN answered -
“Yes, well they are the leading player for HER-2 testing. It's currently a $600 million dollar market and they're the largest player in that market. So we utilised their downstream PathVysion tests for HER-2 in our FDA submission, and we're now in detailed discussions with Abbott about how we can work with them to bring forward a test combining Parsortix and PathVysion. And those conversations are progressing very well.”

radderssandy
03/10/2022
16:00
Hahahahahaha
zeus19
03/10/2022
15:54
Nor do I - it has FDA approval to be sold commercially for MBC.
sicilian_kan
03/10/2022
15:40
I'm not sure what your talking about ... SK ?
amaretto1
03/10/2022
15:24
Could someone help clear something up. Did AN say that a partnership such as with Abbott on the Her2 probe would then require further trials in patients before it could be used commercially. If so, did he give any more details on how long would take? I assume years?

I don't recall him talking about that ahead of FDA but I haven't listned to all the presntations

bagpuss67
03/10/2022
15:19
You should have bought SYME!
1liam
03/10/2022
15:03
When this drops you won't be able to afford a McDonald's
1liam
03/10/2022
14:51
Change the out look ...It would send us in to the stratosphere .... over 200 pence to start.... dictates direction of company....Huge mkt place
amaretto1
03/10/2022
14:48
LESS THAN £1 MILLION IN THE BANK AT THE END OF DECEMBER 22. *NO NEW CONTRACTS *WILL LOSE LAB ACCREDITATIONS*PARTNERSHIP DEALS FALLING APART*PEERS REVIEWING POSITION. *STILL WAITING FIRST FOR FDA APPROVAL. *OVERBOUGHT - Reiterated STRONG SELL
1liam
03/10/2022
14:39
News of an Abbott deal would change the outlook overnight, by itself. They already have the need for Parsortix, on a large scale. Other contracts are smallfry in comparison.
clausentum
03/10/2022
14:36
Well worth listening to the webcast over and over ... a lot has happened over the 4 months - very impressed
givmesunshine
03/10/2022
14:02
It seems that as has been mentioned recently, the Prostate trial collaboration with Solaris Health has been underestimated.
AN indicated that a test would be fast tracked "within" nine months to aid patients. Ovarian has signposted the level of results Parsotix can produce and bodes well for Prostate results & an available fast tracked test within the next few months. A mere blink of the eye in Bio/Medtech time . . .

gooosed
03/10/2022
13:58
I think PI money will slowly pass in to hands of strategic investors.. This does mitigate also of the risk IMO.. We only need a minor few movements on the many developemnts that are being made to turn the share price in a vertical tradjectory..
givmesunshine
03/10/2022
13:45
My target remains 500 pence !!With a 85 percent chance it will achieve this ...
amaretto1
03/10/2022
13:43
I'll educate you ....It matters one jot what the share price has done or been in the past ...i could name you hundreds of stocks that have dropped 90 percent in 2022. The question ..What are the risks with AGL ... the risk been on the company or it's technology ... etc etc ...i cannot find one at present.....Value always lags bio pharmaceutical stocks
amaretto1
03/10/2022
13:36
The only downside is that AN cannot get commercial traction by at least six months before cash runs out mid 2024 and has to try to raise more money. Therefore he has until late 2023. He already has one Pharma contract and that proves it has some traction and over 20 more seriously talking. So, what downside is there? Half of naff all as we are already down 50% since clearance.
purchaseatthetop
03/10/2022
13:33
U odviously don't understand the question.....The downside if material would be far less than 68 pence !
amaretto1
03/10/2022
13:31
We are already in the downside. The price dropped from 160p! The downside is already our bedmate.
purchaseatthetop
Chat Pages: Latest  927  926  925  924  923  922  921  920  919  918  917  916  Older
Your Recent History
LSE
AGL
Angle
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20221208 04:19:19